Greenwood Genetic Center Inc.

Greenwood Genetic Center Inc., doing business as Self Research Institute, is a nonprofit organization headquartered in Greenwood, South Carolina, that delivers specialized genetic testing services and clinical diagnostics to the National Institutes of Health as a prime recipient under federal purchase orders and research grants. The vendor operates exclusively in the full-and-open market with no set-aside designations across its federal footprint.

The center's federal capability portfolio centers on diagnostic laboratory testing for rare genetic disorders, clinical genetic diagnostics for undiagnosed disease programs, and biomedical research into glycosylation pathways and congenital disorders of glycosylation (CDG). Recent prime purchase orders from the National Human Genome Research Institute include a $49,350 contract awarded September 26, 2026, for specialized genetic testing supporting the NHGRI Undiagnosed Diseases Program (clinical protocol 15-HG-0130), which provides laboratory testing for patients with complex, chronic, and previously undiagnosed medical conditions, and an earlier $50,000 award from September 15, 2023, for clinical genetic testing under the same undiagnosed disease program. A third purchase order from May 2, 2022, placed by the National Eye Institute carried $10,000 for DNA testing of patient samples. Beyond contract testing services, the center holds a $284,847 Project Grant from the National Institute of General Medical Sciences (CFDA 93.859), awarded September 3, 2026, to investigate glycosylation and metabolism during tissue development using zebrafish models of PMM2-CDG and other congenital disorders of glycosylation, with performance through June 30, 2031.

Customer concentration is heavily weighted toward the National Institutes of Health and its component institutes. The Department of Health and Human Services National Institutes of Health and subordinate institutes account for 77% of the vendor's awards: the National Human Genome Research Institute (4 awards, $173 thousand combined potential value), the National Institute of General Medical Sciences (4 awards), the National Institute of Neurological Disorders and Stroke (3 awards), and the National Eye Institute (1 award, $10 thousand). The Centers for Disease Control and Prevention (4 awards) rounds out the active customer set. The vendor serves eleven distinct customer agencies across twenty-five prime awards and five sub-awards. Activity has remained modest and episodic — two awards in 2022, two in 2023, one in 2024, three in 2025, and two in 2026 — with two awards (combined potential value $49 thousand) completing in the next twenty-four months.

In its subcontractor role, Greenwood Genetic Center serves as co-investigator on two research projects under a Program Project Grant from Icahn School of Medicine at Mount Sinai (awarded December 9, 2025) focused on neurological pathology mechanisms in congenital disorders of glycosylation, and as a subawardee under a Clemson University COBRE grant (awarded February 1, 2024) for molecular diagnostics advancement and nanopore-based sequencing investigations in inherited retinal disease and unsolved genetic cases. The center's primary NAICS classification is Medical Laboratories, with secondary activity in Other Scientific and Technical Consulting Services, reflecting its posture as a clinical laboratory and research diagnostics provider rather than a traditional contractor.